Chinese COVID vaccine Sinopharm shows tremendous efficacy


Chinese vaccine Sinopharm has already succeeded in proving its efficacy is solid and far-better than AstraZeneca, Pfizer BioNTech, Johnson & Johnson and Moderna. By vaccinating only, a portion of the population, Bangladesh and Pakistan are already witnessing fast decline in the number of COVID cases, while India, even after vaccinating over 50 percent of its population mostly with AstraZeneca is struggling in containing the huge numbers of new cases every day. Similarly, the United States, Britain and the EU countries currently are witnessing massive rise in the number of new cases, while Russia’s Sputnik V vaccine is almost proved to be a total failure.

According to the World Health Organization (WHO), Phase 3 trial of Chinese Sinopharm vaccine has shown that 2 doses, administered at an interval of 21 days have an efficacy of 79 percent against symptomatic SARS-CoV-2 infection 14 or more days after the second dose. Vaccine efficacy against hospitalization was 79 percent.

Chinese vaccines also appear to be working extremely well against the Delta variant. Recent studies suggest that China’s main vaccines from private maker Sinovac and state-owned firm Sinopharm are highly effective in preventing severe illness and death among those fully vaccinated. The studies provide backing for the World Health Organization’s May and June approvals of the jabs from the two Chinese vaccine producers.

In August this year, Abu Dhabi, the capital of the United Arab Emirates, announced that it would require citizens fully vaccinated with Sinopharm jabs to get a third booster dose of Sinopharm or another vaccine. Brazil and Turkey have similarly opted for booster shots. Thailand is employing mix-and-match strategies with Western jabs to bolster the efficacy of Chinese vaccines. Malaysia has begun to phase out the use of Sinovac’s vaccine owing to questions about its efficacy.


Please enter your comment!
Please enter your name here